Iloperidone

Vanda Pharmaceuticals Announces Presentations at SLEEP 2023

Retrieved on: 
Friday, June 2, 2023
Randomness, Patient, Manic, Vanda, Bipolar, Pharmaceutical industry, Iloperidone

WASHINGTON, June 1, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at SLEEP 2023, to be held in Indianapolis, IN from June 3 – 7, 2023.

Key Points: 
  • WASHINGTON, June 1, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at SLEEP 2023, to be held in Indianapolis, IN from June 3 – 7, 2023.
  • The following will be presented:
    Presentation Title: "Effect of Iloperidone on Sleep Symptoms in Bipolar Patients with Manic and Mixed Episodes: A Randomized, Placebo Controlled Study"
    For more information on SLEEP 2023, please refer to https://www.sleepmeeting.org/ .

Shareholder Alert: Robbins Arroyo LLP: Vanda Pharmaceuticals Inc. (VNDA) Sued for Misleading Investors

Retrieved on: 
Monday, July 29, 2019
Legal, Professional services, Chemical compounds, Organic compounds, Common law, Qui tam, United States law, Writs, Iloperidone, Vanda, Pharmaceutical industry, Tasimelteon

Vanda Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of central nervous system disorders.

Key Points: 
  • Vanda Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of central nervous system disorders.
  • Specifically, Vanda schemed to promote its drugs Fanapt and Hetlioz for "off-label" uses in addition to other prohibited promotional strategies.
  • As a result, Vanda is facing significant liability from a Qui Tam lawsuit and has already incurred substantial expenses in its investigation.
  • Vanda has also been named as a defendant in a Securities Class Action lawsuit, causing further damage to the company.

Robbins Arroyo LLP: Vanda Pharmaceuticals Inc. (VNDA) Sued for Misleading Shareholders

Retrieved on: 
Tuesday, February 26, 2019
Professional services, Legal, Chemical compounds, Organic compounds, Iloperidone, Piperidines, Vanda, Pharmaceutical industry in China, Tasimelteon

Vanda is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of central nervous system disorders.

Key Points: 
  • Vanda is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of central nervous system disorders.
  • View this information on the law firm's Shareholder Rights Blog: https://www.robbinsarroyo.com/vanda-pharmaceuticals-feb-19/
    According to the complaint, Vanda owns and markets two drugs Fanapt and Hetlioz.
  • Over the years, Vanda had repeatedly attested to its internal control over financial reporting and the disclosure of all fraud.
  • Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law.

Vanda Wins Denial of Petition For Rehearing on Fanapt®

Retrieved on: 
Tuesday, August 14, 2018
Chemistry, Iloperidone, Piperidines, United States patent law, Organic chemistry

WASHINGTON, Aug. 14, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) announced today that the U.S. Court of Appeals for the Federal Circuit denied petitions for panel rehearing and rehearing en banc filed by West-Ward Pharmaceuticals, a subsidiary of Hikma Pharmaceuticals, relating to Vanda's U.S. Patent number 8,586,610 (the '610 Patent) for Fanapt.

Key Points: 
  • WASHINGTON, Aug. 14, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) announced today that the U.S. Court of Appeals for the Federal Circuit denied petitions for panel rehearing and rehearing en banc filed by West-Ward Pharmaceuticals, a subsidiary of Hikma Pharmaceuticals, relating to Vanda's U.S. Patent number 8,586,610 (the '610 Patent) for Fanapt.
  • This denial by U.S. Court of Appeals for the Federal Circuit leaves undisturbed its prior decision that West-Ward Pharmaceuticals's Abbreviated New Drug Application for iloperidone infringed the '610 Patent, and that West-Ward Pharmaceuticals had not proven the '610 Patent invalid.
  • Vanda is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.
  • For full U.S. Prescribing Information for Fanapt, including indication, Boxed Warnings and Important Safety Information, visit our Web site at www.fanapt.com .